How to evaluate patients with congenital heart disease-related pulmonary arterial hypertension

Expert Rev Cardiovasc Ther. 2019 Jan;17(1):11-18. doi: 10.1080/14779072.2019.1550716. Epub 2018 Dec 6.

Abstract

Patients with congenital heart disease (CHD), who develop pulmonary arterial hypertension (PAH), live longer, and have better quality of life compared to the past due to PAH-specific therapy and improved tertiary care. Areas covered: Clinical examination, objective assessment of functional capacity, natriuretic peptide levels, cardiac imaging, and hemodynamics all play a pivotal role in the evaluation, general care, and management of PAH-specific therapy. This review discusses the epidemiology and pathophysiology of PAH-CHD and provides hints for the optimal evaluation of these patients. Expert commentary: Further research should be performed in the field of PAH-CHD, as there are many of areas lacking evidence that should be addressed in the future. Networking, especially among the tertiary expert centers, could play a key role in this direction.

Keywords: Congenital heart disease; diagnosis; epidemiology; pathophysiology; pulmonary arterial hypertension.

Publication types

  • Review

MeSH terms

  • Heart Defects, Congenital / complications
  • Heart Defects, Congenital / epidemiology
  • Heart Defects, Congenital / physiopathology
  • Humans
  • Hypertension, Pulmonary / diagnosis*
  • Hypertension, Pulmonary / epidemiology
  • Hypertension, Pulmonary / etiology
  • Hypertension, Pulmonary / physiopathology